Home › Ovarian Cancer › North Carolina
Ovarian Cancer clinical trials in North Carolina
44 studies for Ovarian Cancer are looking for participants at sites in North Carolina.
Cities in North Carolina
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Cone Health MedCenter Asheboro, Asheboro
- Cone Health Cancer Center at Alamance Regional, Burlington
- Southeastern Medical Oncology Center-Clinton, Clinton
- and 8 more
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Duke University, Durham
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- Novant Health Cancer Institute - Kernersville, Kernersville
- Novant Health Cancer Institute - Mount Airy, Mount Airy
- Novant Health Forsyth Medical Center, Winston-Salem
Recruiting
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07059884A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Carolina Cancer Research Center, Wilson
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07360314A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0259 - Duke Cancer Center, Durham
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT05128825A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- University of North Carolina Medical Center /ID# 275307, Chapel Hill
- Atrium Health Levine Cancer Institute /ID# 274557, Charlotte
- East Carolina University - Brody School of Medicine /ID# 275770, Greenville
- and 1 more
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT06890338DESTINY-PANTUMOUR04
- Research Site, Durham
- Research Site, Wilson
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- FirstHealth of the Carolinas- Speciality Center /ID# 278636, Pinehurst
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 22, 2026 · NCT07059845A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Duke Cancer Institute, Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213804A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Duke University Medical Center, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213791A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Duke Cancer Center ( Site 0012), Durham
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT07318558Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Levine Cancer Center, Charlotte
- Novant Presbyterian Hospital, Charlotte
- East Carolina University, Greenville
- and 2 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 15, 2026 · NCT07214779Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- Duke, Durham
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 14, 2026 · NCT04575935ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- UNC- Chapel Hill, Chapel Hill
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Charlotte
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT05123482A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- FirstHealth Cancer Center ( Site 0079), Pinehurst
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06824467The Vanguard Study: Testing a New Way to Screen for Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Durham VA Medical Center, Durham
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Sep 2, 2026 · NCT06995898Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Levine Cancer Institute, Charlotte
- East Carolina University, Greenville
- Atrium Health Wake Forest Baptist, Comprehensive Cancer Center, Winston-Salem
RecruitingPhase 3
Ages 18 and older · Women · Updated Aug 26, 2026 · NCT05281471Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- University of North Carolina-Hillsborough Campus, Hillsborough
- Wake Forest University Health Sciences, Winston-Salem
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07001748A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- Atrium Health - Wake Forest, Charlotte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07470853A Study of PHST001 in Advanced Solid Tumors
- Duke Cancer Institute, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06840886A Study of DM002 in Patients With Advanced Solid Tumors
- Carolina BioOncology Institute, LLC, Huntersville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06751329A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Mission Hospital, Asheville
- Hope Women's Cancer Centers-Asheville, Asheville
- Duke Cancer Center Cary, Cary
- and 7 more
Recruiting
Ages 35 to 50 · Women · Updated Aug 7, 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Duke University Medical Center, Durham
- Duke Women's Cancer Care Raleigh, Raleigh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06580314A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Huntersville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07749586A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Atrium Health Wake Forest Baptist - Comprehensive Cancer Center, Winston-Salem
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797The Better, Harder, Faster, Stronger Study
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RecruitingObservational study
Ages 55 and older · Women · Updated Jul 15, 2026 · NCT07220512CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
- Duke University, Durham
RecruitingPhase 1/2
Ages 18 to 75 · Women · Updated Jul 13, 2026 · NCT07322094Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- UNC Hospital, Chapel Hill
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 2, 2026 · NCT06819007Integrated Cancer Repository for Cancer Research
- Cape Fear Valley Health System, Fayetteville
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- GSK Investigational Site, Charlotte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 24, 2026 · NCT04641247Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Carolina BioOncology Institute, Huntersville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT06993844Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
- Lineberger Comprehensive Cancer Center, Chapel Hill
RecruitingPhase 1
Ages 18 and older · Women · Updated May 19, 2026 · NCT06305299Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
- Duke Cancer Center, Durham
- Duke Women's Cancer Care Raleigh, Raleigh
RecruitingPhase 3
Ages 18 and older · Women · Updated Apr 16, 2026 · NCT05659381REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
- Duke Cancer Center, Durham
Recruiting
Ages 18 and older · Women · Updated Apr 13, 2026 · NCT06710548A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
- Site 0259, Durham
RecruitingPhase 1
Ages 18 and older · Women · Updated Apr 7, 2026 · NCT04516447TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
- Duke University Hospital, Durham
Recruiting
Ages 25 to 50 · Women · Updated Apr 6, 2026 · NCT04294927Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
- Levine Cancer Institute (LCI)- Atrium Health, Charlotte
- Duke Cancer Center/ DUMC, Durham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 1, 2026 · NCT05735080A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Duke Cancer Institute, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT06778863From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.